Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. autoimmune disorder
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Autoimmune Disorder Articles & Analysis

27 news found

CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism

CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism

Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and malignancies. To help scientists better understand the regulation and role of mTOR in metabolic regulation and to address ...

ByCD BioSciences


CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. ...

ByCD Genomics


CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

This empowers researchers and pharmaceutical entities to tailor antibody therapies for an extensive array of diseases, ranging from cancer to autoimmune disorders. The Antibody Drug Design Services streamline development timelines, concurrently optimizing costs and increasing the likelihood of success. ...

ByCD ComputaBio


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...

ByCD ComputaBio


Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

About Chronic Kidney Disease in Type 1 Diabetes T1D is a chronic autoimmune disorder characterized by destruction of pancreatic beta cells leading to insulin deficiency and requiring lifelong insulin treatment. ...

ByBayer AG


Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service

Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service

With its advanced technological platform and cutting-edge sequencing and analysis algorithms, this service is designed to accurately and efficiently identify biomarkers that can be used to diagnose or predict the onset of a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. With its ability to identify microbial biomarkers ...

ByCD Genomics


BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

While IVS currently focuses on applications of the LITATM in cardiac safety and discovery projects, IVS has plans for developing a wide range of useful applications in treatment development for regenerative medicine, cancer, autoimmune disorders, and a wide range of rare diseases. Our unique combination of tissue engineering technology with assay automation and ...

ByInvivoSciences, Inc. (IVS)


Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. “With years of experience in lipid chemistry, Alfa Chemistry now provides a full range of fatty acids and esters, ...

ByAlfa Chemistry


Foundation Models for Proteins: Cyrus, OpenFold and the future of biologics

Foundation Models for Proteins: Cyrus, OpenFold and the future of biologics

By doing so we’ll improve our ability to create new biologics from natural proteins, and bring new therapeutics to patients across a wide range of indications from infectious disease vaccines and therapeutics, to rheumatology, to rare disease, and to autoimmune disorders. About Cyrus Biotechnology Cyrus Biotechnology is a pre-clinical-stage biotech ...

ByCyrus Biotechnology Inc.


NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease. For more information, visit www.neximmune.com. ...

ByNexImmune, Inc.


Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the ...

ByJubilant Therapeutics Inc.


Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action Conference

Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action Conference

The presentation titled, “Gut-Brain Axis: How substances produced by the microbiome may contribute to Autism Spectrum Disorder,” will be held on Saturday, April 9 from 1:00-2:00 pm PST. ...

ByAxial Therapeutics Inc.


NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease. For more information, visit www.neximmune.com. ...

ByNexImmune, Inc.


NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease. Dr. Jeffrey Weber is the Chair of NexImmune’s Scientific Advisory Board and receives compensation in connection with that role. ...

ByNexImmune, Inc.


AVM Biotechnology Expands C-Suite in Anticipation of 2023 Commercialization Efforts

AVM Biotechnology Expands C-Suite in Anticipation of 2023 Commercialization Efforts

Preclinical data suggest even greater efficacy in conjunction with chemotherapy as well as potential in solid tumors and autoimmune ...

ByAVM Biotechnology


Nature Medicine Publishes Full Results from Axial Therapeutics’ Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)

Nature Medicine Publishes Full Results from Axial Therapeutics’ Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)

AB-2004 is being studied as a potential new treatment for managing irritability associated with Autism Spectrum Disorder (ASD) in children and is the company’s lead gut-targeted, molecular therapeutic. The article, titled “Safety and target-engagement of an oral small molecule sequestrant in adolescents with Autism Spectrum Disorder: an open-label ...

ByAxial Therapeutics Inc.


Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable safety profile for AB-2004 as ...

ByAxial Therapeutics Inc.


ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

There are an estimated 5.35 million1 people in the United States who suffer from paralysis due to central nervous system disorders, autoimmune diseases, and spinal cord injuries. Blackrock’s MoveAgain BCI system is comprised of an array which, when implanted in the brain, has demonstrated in scientific studies that it can read, analyze, and translate ...

ByClearPoint Neuro, Inc.


Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Global, placebo-controlled Phase 2b trial now enrolling in the U.S., Australia and New Zealand Axial is activating 20 Phase 2b clinical trial sites in the U.S. and seven clinical sites in Australia and New Zealand Clinical studies to date confirm AB-2004’s strong safety profile and potential to address large unmet treatment need in irritability associated with autism spectrum ...

ByAxial Therapeutics Inc.


Immunai Using Acquisition, Funding to Shift Into Functional Work

Immunai Using Acquisition, Funding to Shift Into Functional Work

Dropprint also brings with it profiles of more than a million cells from autoimmune and cancer patients that Immunai will incorporate into its AMICA resource, Solomon said, noting that while Immunai's immune mapping efforts have focused in large part on cancer immunotherapy thus far, the company has always intended to map immune cells across a variety of indications. ...

ByImmunai

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT